The primary objective of most of the large, double-blind, randomized, placebo-controlled trials that have evaluated the cardiovascular effects of GLP-1 RAs in patients with type 2 diabetes focused on evaluating the presence of a MACE, which was defined and generally included cardiovascular death, non-fatal myocardial infarction and nonfatal stroke. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.